Login
Companies $BIOA
$5.21 -$0.01 (0.19%) After hours
BioAge Labs, Inc. logo

BioAge Labs, Inc.

bioagelabs.com

What Do They Do?

Develops experimental medicines for patients with cardiometabolic diseases and eye conditions, using human aging research to identify drug targets.

How Do They Make Money?

Collaboration partners pay upfront and option fees and fund research or development work; agreements may also provide milestone payments and royalties on future product sales.

FY2025 revenue

Who Are Their Customers?

BioAge works with pharmaceutical collaborators, including Lilly and Novartis, through drug-development and target-discovery collaborations.

Customers above 10% of revenue, FY2025
of revenue from one customer

Do Revenues Turn Into Profits?

No. It lost $80.6M in FY2025.

Operating income, FY2025
−1031% of revenue
▼ −19% (Loss) vs FY2024 (−$78.2M)
Net income, FY2025
−896% of revenue
▼ −13% (Loss) vs FY2024 (−$71.1M)
Free cash flow, FY2025
−915% of revenue
▼ −59% (Loss) vs FY2024 (−$51.9M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −85%
vs $2.1M in Q3 FY2025
Net income
▼ −66% (Loss)
vs −$20.2M in Q3 FY2025

Who Do They Compete With?

Competes with Ventyx Biosciences, NodThera, Roche, Merck, Novo Nordisk, AstraZeneca, Neumora, Ventus, Tenvie, Insilico, Brenig, Zydus, Structure Therapeutics, Bristol Myers Squibb, APIE Therapeutics, and Sanofi

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support